BenevolentAI
about founded in of ces in and laboratories in full molecular biology medicinal chemistry and in pharmacology capabilities for in house experimentation pipeline platform generated disease programmes atopic dermatitis asset in phase i novel target for asset in enabling studies novel target selected by as part of successful collaboration in driven drug hypothesis led to approval of drug for covid reduction in mortality validated platform and engine from to clinical development platform and knowledge graph leverage a wealth of peer reviewed research and diverse data to build a broad spectrum of evidence complex disease biology years investment in data curation relationship extraction models development result in generation of proprietary insights at cant scale data introspection tools deliver factorial analysis and perform real time in silico experimentation to validate targets industry unique approach drives higher con decisions downstream and accelerates the development of risked novel drug candidates benevolent | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
9 of 42
Related slides by other companies
Absci
Investor Conference
January 2023
technology validated through industry leading partnerships | Absci
AbCellera
Investor Conference
January 2024
continued focus on high value programs and strategic partnerships with our differentiated technology position in liquidity we have a long cash runway for focused investment execution completion of engine over the next years we will continue to invest in the final stage of our engine including construction commissioning of our manufacturing facility our portfolio of partnered in we anticipate partnership deals from our cell engager platform our partnership strategy is to select high value not deal volume our portfolio of internal we expect to enter clinical development in in we expect additional first in class development candidates from our ion channel platform | AbCellera
Alkermes
Investor Conference
January 2024
proven drug development capabilities | Alkermes
AvePoint
Investor Presentation
November 2022
why we win depth and breadth of platform comprehensive data strategy platform approach benefits | AvePoint
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io